|

楼主 |
发表于 9-10-2009 09:21 PM
|
显示全部楼层
原帖由 m.i.k.e 于 9-10-2009 08:05 PM 发表 
SPPI
6.21
-0.21 (-3.27%)
Pre-market: 5.13 -1.08 (-17.39%)
我也输了。。。
战败。。。。。看来要啃面包了。。。。 |
|
|
|
|
|
|
|
发表于 9-10-2009 09:46 PM
|
显示全部楼层
|
|
|
|
|
|
|
发表于 11-10-2009 02:02 PM
|
显示全部楼层
轉帖:
CVM
http://finance.google.com/group/ ... d05ce0f02fc8?hl=en#
When you invest in Bio tech stocks you have to invest on some basic
fundamentals - like
1)Advanced Cutting edge technology the company is working on,
2)The products in the pipeline ,
3) and most importantly the amount of money the company has in its
bank to last.
We are the few fornutate folks who have the CVM stock and we must not
get too shaken by some financial analyst writing about a company who
are I think in many ways could create the next generation Immuno
therapy products That will not only save millions of lives but also
reduce the chances of getting those diseases.
Coming to LEAPS H1N1 Emergency drug at this point of time We are told
by the CDC that the vaccines are ready and will be shipped in millions
in the weeks to come. But they also said that CDC is still expecting a
lot of very ill h1n1 patients and deaths as a result of the same .
This tells me that CDC Thinks that Tamiflu and Relenza that are
approved as emergency drugs for H1N1 may not work for all and the
Vaccines are fine to tackle the current strain but not any mutations
of the same.
The Swine flu came to mexico in April is very unsual --- Considering
that its quite warm by then in Down south and Flu season is considered
to be over and then travelled around the world in the summer months
means that this virus is very very potent and different and may also
mutate.
At this point of time there are no company in the US I know of that
has advanced with tackling swine flu the way Cel-sci has . The reason
is They came out with LEAPS tecnology way back in 2005-06 and
proposed a cure for Arthirities using the same .
Multikine has a very very high chance of getting FDA approval as
published in the top Medical journals like http://www.pharmalive.com
and biomedreports .... Lets not forget Multikine will be first line
of defence for any kind of cancer and will also be used in patients
with Head and neck cancer .
In a year or so I expect to see this stock anywhere between $40 and
$50 which means that total market cap of around $7B and thats a
conservative estimate.
I am sure lot of us are saying that first let it reach $4 so my ass
is covered , then we can wait for the $40 ... when things happen it
will happen so quickly that it will be too late for individual
investors like us to own 10k plus shares of CVM ... so pile up as
you can till this uncertainty lasts |
|
|
|
|
|
|
|
发表于 11-10-2009 09:13 PM
|
显示全部楼层
轉帖:
The reason why I am investing in this company.
Multikine Primed for Success (slide 19)
CEL-SCI is poised to begin the final phase (pivotal Phase III) of human clinical studies for Multikine:
•Study is cleared by both the FDA and the Canadian regulators; the goal of the study is to receive marketing approval world-wide
• artnered with Teva Pharmaceuticals and Orient Europharma
•Full scale, commercial ready manufacturing facility is built out
Multikine success in Phase I and II clinical trials:
•Safe and non-toxic in 220 patients
•12% of patients have NO TUMOR LEFTafter 3 week treatment
•50% fewer tumor cells in treated group after 3 week treatment
•33% improvement in overall survival over standard of care treatment at median 3.5 years in key Phase II study
Success would bring us into the biggest market of all – the first line treatment, just after the patient is diagnosed. |
|
|
|
|
|
|
|
发表于 11-10-2009 09:14 PM
|
显示全部楼层
轉帖:
How we attempt to reduce the risk of failure of our Phase III trial
The most common reasons for Phase III study failures or failure to receive approval to sell a drug, other than the drug not working, are:
1.Phase III study not reviewed by FDA and not acceptable to FDA: Our Phase III study was reviewed in detail and we made changes based on FDA’s comments prior to commencement of the Phase III trial.
2.Study too small:Our study will enroll 800 patients, a very large number.
3.Clinical endpoint not relevant:We follow overall survival of the patients, the gold standard. The clinical endpoint cannot be more relevant.
4.Change in treatment protocol between Phase II and Phase III without additional studies: We have made no changes. Therefore we expect the Phase II results to be representative of the results one can expect in the Phase III trial.
5.Insufficient attention to manufacturing issues: We have validated our manufacturing process and built a dedicated manufacturing facility for Multikine. |
|
|
|
|
|
|
|
发表于 12-10-2009 11:07 PM
|
显示全部楼层
|
|
|
|
|
|
|
发表于 12-10-2009 11:20 PM
|
显示全部楼层
原帖由 miku 于 12-10-2009 11:07 PM 发表 
芬芬,cvm最快几时有消息?谢谢
請參考我的151樓。。。
P/s: 題外話: 今天只說了幾句話,還給人Shoot 回說是自私的中國人! 
[ 本帖最后由 葉芬 于 12-10-2009 11:21 PM 编辑 ] |
|
|
|
|
|
|
|
发表于 13-10-2009 12:51 AM
|
显示全部楼层
|
|
|
|
|
|
|

楼主 |
发表于 13-10-2009 05:12 PM
|
显示全部楼层
原帖由 m.i.k.e 于 13-10-2009 04:51 PM 发表 
给人shoot 是活该.....自己的功课不做,却走去做个多管闲事的中国人.
之前说的 YONG 和 Cardium Therapeutics Inc. 都往上升了. 你有没有买进啊?
YONG
11.27 +0.54 (5.03%)
After Hours: 11.40 +0.1 ...
昨晚 开市 时 偏低。。。。
mike , 你买了吗?? |
|
|
|
|
|
|
|
发表于 13-10-2009 06:55 PM
|
显示全部楼层
|
|
|
|
|
|
|
发表于 13-10-2009 08:18 PM
|
显示全部楼层
題外話:
最近發現到好多位在馬的紅牌都會溜來國際區溜溜。。。
難道是美股吸引了他們??
 |
|
|
|
|
|
|
|
发表于 14-10-2009 03:52 AM
|
显示全部楼层
Posted by: BlackThought Date: Tuesday, October 13, 2009 12:30:29 PM
In reply to: roger wilco who wrote msg# 1713 Post # of 1719
" I spoke with Dan
CVM is working towards Plant being validated for both LEAPS and Multikine. FDA is working to speed up validation for H1N1 LEAPS. Would not say when validation is expected. Everyone is working for it to be ASAP. Dan said that with the FDA wanting LEAPS testing to be fast they are expecting the FDA to be fast in helping the plant to be validated.
Asked if several friends could join Phase III trials for Multikine. Dan said they already have patients lined up but have their doctor contact CVM.
Dan stated that FDA 'could' authorize sale of Multikine during Phase III trials.
When I asked if the new hires posted on their web site have to be in place for the plant validation Dan stated that they have proper people in place for validation to occur.
I asked why he was in place. He stated that they needed PR help. They have $20M to finish Phase III and CVM is now spending it.
I asked if we would hear any news from Brazil before FDA and he said the next news would come from FDA.
When I asked if LEAPS needed to be manufactured in a cold fill facility he said he did not know.
I asked if the NIH was involved with testing LEAPS. Dan said they have hired a CRO. I wonder what the NIH is doing?
Dan was very patient with me. I was asking a lot of questions.
When I asked how they felt about Adam F he said the he was an American and can say what ever he wants but the company will release information in due time that explains developments for CVM."
Dan Schustack seems to be the new IR guy.
http://www.linkedin.com/pub/dan-schustack/5/23/48b |
|
|
|
|
|
|
|
发表于 14-10-2009 07:19 AM
|
显示全部楼层
|
|
|
|
|
|
|
发表于 14-10-2009 09:32 AM
|
显示全部楼层
YONG
Confirm 了......Timothy 买 11.05 x 2000units, 隔天卖 11.66, 赚$1202......果然是一流的短炒高手.
我还捉着不放,是不是又太贪了?...... |
|
|
|
|
|
|
|
发表于 14-10-2009 09:34 AM
|
显示全部楼层
|
|
|
|
|
|
|
发表于 14-10-2009 09:36 AM
|
显示全部楼层
|
|
|
|
|
|
|
发表于 14-10-2009 09:39 AM
|
显示全部楼层
|
|
|
|
|
|
|
发表于 14-10-2009 09:45 AM
|
显示全部楼层
|
|
|
|
|
|
|
发表于 14-10-2009 09:46 AM
|
显示全部楼层
|
|
|
|
|
|
|
发表于 14-10-2009 12:33 PM
|
显示全部楼层
|
|
|
|
|
|
| |
本周最热论坛帖子
|